IPP Bureau
Government allocates over Rs. 10,000 Cr in PLI scheme for bulk drugs and medical devices: Gowda
By IPP Bureau - February 26, 2021
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
Granules India gets USFDA approval of acetaminophen, aspirin and caffeine tablets
By IPP Bureau - February 25, 2021
ranules now has a total of 38 ANDA approvals from US FDA.
Aurobindo Pharma to acquire 26% ownerships solar power companies
By IPP Bureau - February 24, 2021
The company will be holding 26% of the share capital in each of the solar power generating companies.
USFDA denies Sun Pharma Advanced Research’s appeal of NDA for Taclantis
By IPP Bureau - February 24, 2021
The company will review FDA's response and decide on appropriate next steps soon.
Thermo Fisher’s new facility in Bengaluru to produce reliable COVID-19 testing kits
By IPP Bureau - February 23, 2021
Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.
“Minus 20°C is sometimes trickier than minus 70°C”
By IPP Bureau - February 22, 2021
DHL and other logistics companies were already transporting pharmaceutical products at minus 70°C in Schaumaplast boxes packed with dry ice before the coronavirus pandemic
Unichem Laboratories receives ANDA approval for Apremilast Tablets
By IPP Bureau - February 20, 2021
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .
Zydus Cadila receives final approval from USFDA for Droxidopa capsules
By IPP Bureau - February 20, 2021
It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.
Lupin receives approval for Droxidopa capsules
By IPP Bureau - February 20, 2021
Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness
Dr. Reddy's initiates process for emergency use authorization of Sputnik V
By IPP Bureau - February 20, 2021
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
Dr. Reddy's Laboratories launches FH Tablets in the U.S. Market
By IPP Bureau - February 19, 2021
Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.
Granules India announces approval of Potassium Chloride ER Capsules
By IPP Bureau - February 18, 2021
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
Lupin launches posaconazole delayed-release tablets
By IPP Bureau - February 18, 2021
posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.
Steady quarter with margin improvement for Glenmark: ICICI Securities
By IPP Bureau - February 17, 2021
India business grew 11.8% YoY vs mid-single digit industry growth.
Glenmark Q3 FY21 net profit up 30% at Rs 248 Cr
By IPP Bureau - February 15, 2021
The jump in profit is due to the better performance of the API business.
